Literature DB >> 19762505

Reduced-intensity conditioning allogeneic stem cell transplantation in HIV patients with hematologic malignancies: yes, we can.

Mehdi Hamadani, Steven M Devine.   

Abstract

Entities:  

Mesh:

Year:  2009        PMID: 19762505     DOI: 10.1182/blood-2009-06-229666

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  4 in total

1.  Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial.

Authors:  Richard F Ambinder; Juan Wu; Brent Logan; Christine M Durand; Ryan Shields; Uday R Popat; Richard F Little; Deborah K McMahon; Joshua Cyktor; John W Mellors; Ernesto Ayala; Lawrence D Kaplan; Ariela Noy; Richard J Jones; Alan Howard; Stephen J Forman; David Porter; Carlos Arce-Lara; Paul Shaughnessy; Lisa Sproat; Shahrukh K Hashmi; Adam M Mendizabal; Mary M Horowitz; Willis H Navarro; Joseph C Alvarnas
Journal:  Biol Blood Marrow Transplant       Date:  2019-07-04       Impact factor: 5.742

2.  Allogeneic hematopoietic stem cell transplantation in a patient with HIV-negative recurrent plasmablastic lymphoma: A case report.

Authors:  Chunmeng Rong; Lixia Sheng; An Wu; Ye Sun; Guifang Ouyang
Journal:  Medicine (Baltimore)       Date:  2021-02-19       Impact factor: 1.817

3.  Bortezomib, Lenalidomide and Dexamethasone Combination Induced Complete Remission in Relapsed/Refractory Plasmablastic Lymphoma: Case Report of a Potential Novel Treatment Approach.

Authors:  Waleed Sabry; Yue Wu; Shruthi Ganeshappa Kodad
Journal:  Curr Oncol       Date:  2022-07-18       Impact factor: 3.109

4.  Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham's Lymphangiomatosis: Review of the Literature.

Authors:  Matthew Lee; Beth A Martin; Haifaa Abdulhaq
Journal:  Case Rep Hematol       Date:  2022-06-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.